Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05119296 · ClinicalTrials.gov registry record · Phase 2

Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

A Phase 2 study of Thyroid Cancer, sponsored by Stanford University.

Active
Registry status
Phase 2
Development phase
12
Enrollment target
1
Study location

NCT05119296: Active Phase 2 study of Thyroid Cancer, sponsored by Stanford University.

NCT05119296 is a Phase 2 study of Thyroid Cancer that is active but no longer recruiting, run by Stanford University. The registered enrollment target is 12 participants, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05119296, a Phase 2 study of Thyroid Cancer, is active but no longer recruiting, sponsored by Stanford University.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
12 participants
Enrollment target
1
Study location

Study Summary

This is a single-arm, open-label trial designed to evaluate the activity of pembrolizumab therapy in anaplastic thyroid cancer in patients with no curative alternative therapy. Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, withdrawal of consent or death

Conditions Studied

Thyroid Cancer

Interventions

  • DRUG Pembrolizumab (Keytruda)

Study Locations (1)

California

  • Stanford University - Palo Alto

Trial Details

FieldValue
Enrollment Target 12 participants
Start Date 2022-02-15
Est. Completion 2026-09-01
Phase Phase 2

Sponsor

Stanford University

1,744 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05119296

The ClinicalTrials.gov registry entry for NCT05119296 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Pembrolizumab (Keytruda) is the first listed.

NCT05119296 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT05119296 about?

NCT05119296 is a clinical study titled "Phase II Trial of Pembrolizumab in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer". This is a single-arm, open-label trial designed to evaluate the activity of pembrolizumab therapy in anaplastic thyroid cancer in patients with no curative alternative therapy. Pembrolizumab (Keytruda-Merck) 200 mg, given IV every 3 weeks, until evidence of progression, intolerance of treatment, wit...

What is the current status of trial NCT05119296?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2022-02-15. Estimated completion is 2026-09-01.

What conditions does trial NCT05119296 study?

This clinical trial studies the following conditions: Thyroid Cancer.

What interventions are being tested in trial NCT05119296?

The interventions under investigation include: Pembrolizumab (Keytruda) (DRUG).

Who is sponsoring clinical trial NCT05119296?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05119296 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Thyroid Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.